Earlier this month, I read something in the Amyloidosis News Today newsletter that rekindled my curiosity about the investigational gene-editing therapy nexiguran ziclumeran (nex-z).
Heart to Heart Connection - a Column by Jade River
ATTR-CM
ColumnsTaiwan’s summer heat teaches us to live a calm, slow life
In the middle of a heat wave in the United States, I flew to Taiwan to visit my parents. Even though I had just acclimated…
Columns
by Jade River
Anniversary of mom’s amyloidosis diagnosis brings hope, gratitude
I joined my mom’s cardiology appointment remotely last week. It marked the one-year anniversary of her diagnosis, and her doctor ordered a few tests to…
A good friend of mine sadly passed away last month in a hospital in New York City. When I received the news, I couldn’t believe…
ATTR-CM
ColumnsUnderstanding the patient’s perspective in a fast-paced world
I was sick for more than a week recently. The slow recovery gave me a glimpse into a chronic disease patient’s point of view —…
Illness casts a shadow over the lives of both the patient and the caregiver. In my family’s situation, my mom, Feng-Ying Wu, is the patient,…
ATTR-CM
ColumnsMental flexibility is key to coping with my role as a caregiver
When I first found myself in an intense caregiving role last year, I promised to stay strong for my mom, the patient, and my dad,…
On Mother’s Day last year, by chance or instinct, I was awake past midnight when I received the message that my mom, Feng-Ying Wu, had…
Recent Posts
- New data suggest ATTR-CM therapy may help reverse heart damage
- ATTR-CM therapy shows consistent effects across treatment groups
- Machine learning IDs family history, carpal tunnel as ‘red flags’ in hATTR
- Trial now testing long-term effects of approved ATTR-CM treatment
- Experts recommend early gene-silencing treatment for hATTR-PN